These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 5664503)
1. Toxicity of new drugs. Lowinger P Science; 1968 Aug; 161(3842):632. PubMed ID: 5664503 [No Abstract] [Full Text] [Related]
2. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy. Simmons HE Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901 [No Abstract] [Full Text] [Related]
3. A perspective on US drug reimportation. Choudhry NK; Detsky AS JAMA; 2005 Jan; 293(3):358-62. PubMed ID: 15657329 [No Abstract] [Full Text] [Related]
4. CONTROL OF DRUG TOXICITY IN THE UNITED STATES OF AMERICA. WESTON JK; WESTON K Practitioner; 1965 Jan; 194():16-21. PubMed ID: 14259685 [No Abstract] [Full Text] [Related]
5. FDA moves closer to new requirements for NTI drugs. Traynor K Am J Health Syst Pharm; 2011 Sep; 68(17):1568-9, 1570. PubMed ID: 21856797 [No Abstract] [Full Text] [Related]
8. Nonprescription drugs: an overview. Hodes B Int J Health Serv; 1974; 4(1):125-30. PubMed ID: 4829892 [No Abstract] [Full Text] [Related]
9. Adverse drug reactions: definition of the problem. Dunlop D Am J Epidemiol; 1971 Nov; 94(5):403-4. PubMed ID: 5120537 [No Abstract] [Full Text] [Related]
10. An Open Letter to Health Canada. Papp K; Albrecht L; Barber K; Bourcier M; Dion PL; Freiman A; Gooderham M; Guenther L; Gulliver W; Hong CH; Lynde C; Poulin Y; Siddha S; Toole J; Toth D; Vender R; Wasel N; Wiseman M J Cutan Med Surg; 2017; 21(3):195-196. PubMed ID: 28903599 [No Abstract] [Full Text] [Related]
11. What to do until the FDA arrives. Riegelman RK Postgrad Med; 1981 Dec; 70(6):103-8. PubMed ID: 7031627 [TBL] [Abstract][Full Text] [Related]
12. Adequate controls for new drugs: good manufacturing practice and the 1938 federal Food, Drug, and Cosmetic Act. Cooper DE Pharm Hist; 2002; 44(1):12-23. PubMed ID: 12068915 [No Abstract] [Full Text] [Related]
13. Present attitudes of governmental drug regulatory agencies. Noel PR Int J Clin Pharmacol; 1973 Apr; 7(2):168-77. PubMed ID: 4731283 [No Abstract] [Full Text] [Related]
14. Drug review and postmarketing surveillance programs are sound, but systems approach to risk management is needed, says FDA. Miller JL Am J Health Syst Pharm; 1999 Jul; 56(13):1294,6. PubMed ID: 10683122 [No Abstract] [Full Text] [Related]
15. [Problems connected with the drug provision in the United States]. Sloot HA Pharm Weekbl; 1969 Jul; 104(30):914-23. PubMed ID: 5800761 [No Abstract] [Full Text] [Related]
17. Editorial: The drug makers. Med J Aust; 1974 Oct; 2(16):583-4. PubMed ID: 4437418 [No Abstract] [Full Text] [Related]
18. New DTCA Guidance--Enough to Empower Consumers? Robertson CT N Engl J Med; 2015 Sep; 373(12):1085-7. PubMed ID: 26287748 [No Abstract] [Full Text] [Related]
19. Plans to reduce drug risks examined. Young D Am J Health Syst Pharm; 2007 Aug; 64(15):1568, 1574, 1578. PubMed ID: 17646555 [No Abstract] [Full Text] [Related]
20. The development of drugs and the responsibilities involved. Weston JK Ann N Y Acad Sci; 1967 Mar; 141(1):24-34. PubMed ID: 5232235 [No Abstract] [Full Text] [Related] [Next] [New Search]